Search Results

You are looking at 51 - 60 of 110 items for :

  • "aromatase inhibitor" x
  • Refine by Access: All x
Clear All
Full access

Jonas A. de Souza, Mark J. Ratain, and A. Mark Fendrick

endocrine therapy with aromatase inhibitors (AIs) for women with hormone receptorpositive breast cancer is a prime example. Although some data support AI use for 5 years based on randomized clinical trials, evidence is still unclear beyond this duration, and

Full access

Robert W. Carlson, Susan Moench, Arti Hurria, Lodovico Balducci, Harold J. Burstein, Lori J. Goldstein, William J. Gradishar, Kevin S. Hughes, Mohammad Jahanzeb, Stuart M. Lichtman, Lawrence B. Marks, Joan S. McClure, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Mary Lou Smith, Neal S. Topham, Tiffany A. Traina, John H. Ward, and Eric P. Winer

aromatase inhibitors. 27 , 28 Life Expectancy Estimation of survival was identified by many task force participants as a key factor in making treatment decisions for older women with breast cancer. Data from the U.S. Centers for Disease Control and

Full access

Cindy Railton, Sasha Lupichuk, Jennifer McCormick, Lihong Zhong, Jenny Jaeeun Ko, Barbara Walley, Anil A. Joy, and Janine Giese-Davis

to aromatase inhibitors (AIs). Analysis To summarize demographic, chart review, pharmacy, and interview data, we used descriptive statistics, SAS 9.3, and 2-tailed tests. Using chi-square and Fisher exact tests, we compared PCP versus cancer

Full access

Azeez Farooki

with various cancer therapies, including aromatase inhibitor (AI) therapy in postmenopausal women and AI therapy and gonadotropin-releasing hormone (GnRH) agonists in pre-menopausal women with breast cancer, bone marrow transplantation in patients with

Full access

Somasundaram Subramaniam, Jason A. Zell, and Pamela L. Kunz

improving progression-free survival in patients with hormone receptor-positive advanced breast cancer previously treated with nonsteroidal aromatase inhibitors. Common side effects of everolimus include stomatitis, rash, diarrhea, fatigue, and upper

Full access

Therese B. Bevers

aromatase inhibitors (AIs) exemestane and anastrozole have shown even greater breast cancer risk reduction for women at increased risk of developing the disease. 5 , 6 However, the trials were small and these agents are not currently FDA-approved for this

Full access

Scott Ramsey and Veena Shankaran

: 36 – 46 . 23 Sedjo RL Devine S . Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer . Breast Cancer Res Treat 2011 ; 125 : 191 – 200 . 24 Kelley RK Venook AP

Full access

Julia C. Shih and Anthony J. Olszanski

. 6 Within cancer care, the earliest reports of nonadherence rates were documented in breast cancer with endocrine therapies, ranging from 12% to 59% with tamoxifen and 9% to 50% with aromatase inhibitors. 7 In a systematic review by Greer et al, 1

Full access

Presenter: William J. Gradishar

cells become resistant to antiestrogen therapy. With knowledge of these pathways, these targets became druggable, he said. Figure 2. Examples of hormonal therapies for ER+ breast cancer: evidence of recent acceleration. Abbreviations: AI, aromatase

Full access

Jing Xi, Aabha Oza, Shana Thomas, Foluso Ademuyiwa, Katherine Weilbaecher, Rama Suresh, Ron Bose, Mathew Cherian, Leonel Hernandez-Aya, Ashley Frith, Lindsay Peterson, Jingqin Luo, Jairam Krishnamurthy, and Cynthia X. Ma

significantly improve PFS compared with hormone therapy alone in patients with advanced HR+/HER2– breast cancer, 6 , 7 leading to FDA approval of palbociclib in combination with an aromatase inhibitor (AI; as first-line therapy) in February 2015, and with